ArticleBritish journal of cancer1996
Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma.
Article in British journal of cancer, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 82 citations in OpenAlex.
- Immunohistochemical Markers and TILs Evaluation for Endometrial Carcinoma.Journal of clinical medicine · 2022Article
- Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2020Review
- The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.International journal of molecular sciences · 2019Review
- Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression.Oncology letters · 2019Article
- Validation of Molecular Typing for Endometrial Screening Test That Predicts Benign and Malignant Lesions.Frontiers in oncology · 2019Article
- Modeling the Etiology of p53-mutated Cancer Cells.The Journal of biological chemistry · 2016Article
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2016Article
- Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironment.Oncogene · 2015Article
- Nuclear and cytoplasmic p53 suppress cell invasion by inhibiting respiratory complex-I activity via Bcl-2 family proteins.Oncotarget · 2014Article
- Biomarkers in endometrial cancer: Possible clinical applications (Review).Oncology letters · 2012Article
- P53 and BCL-2 as prognostic markers in endometrial carcinoma.Pathology oncology research : POR · 2008Article
- P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.Clinical & experimental metastasis · 2007Article
- Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas.Virchows Archiv : an international journal of pathology · 2005Article
- Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.Journal of cancer research and clinical oncology · 2003Article
- Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations.The Histochemical journal · 2001Article
- Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer.British journal of cancer · 2000Article
- Independent prognostic importance of microvessel density in endometrial carcinoma.British journal of cancer · 1998Article
- Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings.Journal of cancer research and clinical oncology · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The important role of the p53 gene in tumour progression and cellular response to DNA damage has prompted investigation of the clinical significance of alterations to this gene. We examined both p53 overexpression and mutation of the gene in endometrial carcinoma in order to evaluate the prognostic significance of these changes. Of 122 endometrial carcinomas, 33 (27%) showed overexpression of p53 in the nucleus and 66 (54%) in the cytoplasm. Mutation in the p53 gene was found in 16 (13%) cases but showed no significant association with patient survival. Nuclear p53 overexpression was associated with poor survival (48% vs 80% alive in negative tumours 5 years post operatively, P < 0.001). In contrast, cytoplasmic p53 overexpression was associated with better survival (85% vs 55%, P < 0.001). When patients were separated into prognostic subgroups according to established clinical markers, these associations remained significant within most subgroups examined. In multivariate analysis adjusted for surgical stage, histological grade and type and vascular invasion, both nuclear p53 overexpression [hazard ratio 4.9 (95% CI 1.3-17.6). P = 0.016] and cytoplasmic overexpression [0.25 (0.06-0.98), P = 0.047] were independent prognostic factors. Immunohistochemical assessment of p53 overexpression in the nucleus and cytoplasm could provide useful prognostic information for the management of patients with endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.